Foundation Medicine Introduces Innovative Germline Tests
Foundation Medicine, a pioneering genomics company focused on transforming cancer care, has announced its plans to introduce two exciting new products: FoundationOne Germline and FoundationOne Germline More. These new germline tests will be available in the United States to enhance the identification of genetic variants associated with hereditary cancers. With the help of Fulgent Genetics, Inc. (NASDAQ: FLGT), healthcare providers will soon be able to integrate these tests into their genomic profiling processes.
Details of the FoundationOne Germline Tests
The FoundationOne Germline test is a cutting-edge next-generation sequencing (NGS) tool that examines 50 specific genes known to be associated with hereditary cancers. This test is particularly beneficial for individuals who have a personal or family history indicative of such conditions. In addition, the FoundationOne Germline More expands the analysis to 154 genes, incorporating both established cancer-related genes and emerging candidate genes with proven associations to cancer risk. This expanded test is tailored for individuals displaying complex clinical backgrounds and family histories who require more in-depth genetic analysis.
Impact on Healthcare Providers and Patients
The insights derived from these germline tests are invaluable, as they assist healthcare providers in understanding not only the origin of the patient’s cancer but also their potential cancer risk in the future. Annie Murphy, Chief Commercial Officer at Foundation Medicine, emphasizes the need for comprehensive information in treatment decision-making. She expresses enthusiasm about the added value this new offering brings to both healthcare professionals and patients.
Combining Powers for Comprehensive Care
Both FoundationOne tests leverage Fulgent’s advanced technology platform, which specializes in analyzing single nucleotide and copy number variations. When combined with Foundation Medicine's other comprehensive genomic profiling tests—including FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne Heme, and FoundationOne RNA—these germline tests will enable healthcare providers to cultivate a thorough molecular profile for their patients.
Strengthening Oncological Collaboration
As Brandon Perthuis, Chief Commercial Officer at Fulgent, points out, the synergy between germline and somatic testing represents a critical advancement in cancer diagnostics. This partnership focuses on enhancing the quality of care provided to patients through the collaboration of two leading companies, both strong in their fields.
Foundation Medicine's Commitment to Cancer Care
Foundation Medicine holds a pivotal role in molecular profiling for cancer, dedicated to advancing the landscape of clinical care and research. The company collaborates with numerous partners in the cancer community and aspires to uphold the highest standards of quality and scientific integrity. Their profound understanding of cancer biology empowers physicians to make informed treatment decisions while aiding researchers in the development of innovative therapies.
Your Partner in Precision Medicine
Every day, Foundation Medicine strives to assist its partners in discovering solutions that improve patient outcomes, enabling advancements in precision cancer care across the globe. As part of their offerings, resources and information are readily available for those interested in learning more about their important work.
About Fulgent Genetics
Fulgent is a distinguished technology company which has built a solid reputation in laboratory services and therapeutic development. The company specializes in providing technical lab services and thorough professional analysis of laboratory results by licensed physicians. Its therapeutic development branch is dedicated to creating drug candidates aimed at treating various types of cancers utilizing a unique nanoencapsulation and targeted therapy platform, ultimately aiming to evolve into a fully integrated precision medicine enterprise.
Frequently Asked Questions
What are the FoundationOne Germline tests?
FoundationOne Germline and FoundationOne Germline More are genomic tests designed to identify genetic variants that are related to hereditary cancers.
Who can benefit from these tests?
These tests are suitable for individuals with a personal or family history of hereditary cancers who need a clearer understanding of their genetic risks.
How many genes do these tests analyze?
The FoundationOne Germline analyzes 50 genes, while the expanded FoundationOne Germline More tests 154 genes.
What is the significance of the partnership with Fulgent?
This partnership combines Fulgent's technology with Foundation Medicine's expertise, allowing for more comprehensive cancer genetic profiling.
What is the overall goal of Foundation Medicine?
Foundation Medicine aims to improve cancer care by providing physicians with the information needed to make better-informed treatment decisions for their patients.
